Drug profile · INN
lapatinib ditosylate
LAPATINIB DITOSYLATE
lapatinib ditosylate (LAPATINIB DITOSYLATE) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — lapatinib ditosylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 13
- Data quality
- 0.89
Quick answer
lapatinib ditosylate (LAPATINIB DITOSYLATE) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Receptor protein-tyrosine kinase erbB-2 inhibitor
Primary target: Epidermal growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lapatinib ditosylate?
lapatinib ditosylate (LAPATINIB DITOSYLATE) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lapatinib ditosylate?
LAPATINIB DITOSYLATE is a marketed brand name for lapatinib ditosylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lapatinib ditosylate?
lapatinib ditosylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.